Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies

Br J Haematol. 2019 Jul;186(1):175-180. doi: 10.1111/bjh.15784. Epub 2019 Feb 10.

Authors

Affiliations

¹ University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² German CLL Study Group, University of Cologne, Cologne, Germany.
³ University of Rochester Cancer Center, Rochester, NY, USA.
⁴ Centre Hospitalier Universitaire Bordeaux, Bordeaux, France.
⁵ Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
⁶ The Ohio State University, Columbus, OH, USA.
⁷ Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA.
⁸ Azienda Ospedaliera Niguarda Cà Granda, Milan, Italy.

PMID: 30739324
DOI: 10.1111/bjh.15784

No abstract available

Keywords: Bruton's tyrosine kinase inhibitor; chronic lymphocytic leukaemia; comorbidities; ibrutinib; survival outcomes.

Publication types

Comparative Study
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adenine / analogs & derivatives
Adult
Aged
Aged, 80 and over
Comorbidity
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / mortality
Male
Middle Aged
Piperidines
Pyrazoles / therapeutic use*
Pyrimidines / therapeutic use*
Survival Analysis

Substances

Piperidines
Pyrazoles
Pyrimidines
ibrutinib
Adenine